Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.

Blood
Thierry FaconJesus San-Miguel

Abstract

The phase 3 CLARION study compared carfilzomib-melphalan-prednisone (KMP) with bortezomib-melphalan-prednisone (VMP) in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. Patients were randomized 1:1 to KMP or VMP for nine 42-day cycles (C). Patients received carfilzomib on days (D) 1, 2, 8, 9, 22, 23, 29, 30 (20 mg/m2: C1D1, C1D2; 36 mg/m2 thereafter) or bortezomib on D1, 4, 8, 11, 22, 25, 29, 32 (1.3 mg/m2; D4, 11, 25, 32 omitted for C5-9). Melphalan (9 mg/m2) and prednisone (60 mg/m2) were administered on D1-4. The primary endpoint was progression-free survival (PFS). Nine hundred fifty-five patients were randomized (intention-to-treat population: KMP, n = 478; VMP, n = 477). Median PFS was 22.3 months with KMP vs 22.1 months with VMP (hazard ratio [HR], 0.906; 95% confidence interval [CI], 0.746-1.101; P = .159). Median overall survival was similar and not reached in either group (HR, 1.08; 95% CI, 0.82-1.43). Overall response rate was 84.3% for KMP and 78.8% for VMP. Complete response rate was 25.9% for KMP and 23.1% for VMP. Minimal residual disease-negative rates were 15.7% (KMP) and 15.5% (VMP). Adverse events (AEs) of interest (any grade) occurring with a ≥5% higher patient incidence in the KMP arm...Continue Reading

References

Apr 27, 2005·Evaluation & the Health Professions·Kathleen J Yost, David T Eton
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Nov 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kim CocksJulia M Brown
Feb 5, 2011·Blood·S Vincent RajkumarUNKNOWN International Myeloma Workshop Consensus Panel 1
May 11, 2012·The New England Journal of Medicine·Antonio PalumboUNKNOWN MM-015 Investigators
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jesús F San MiguelPaul G Richardson
Sep 4, 2014·The New England Journal of Medicine·Lotfi BenboubkerUNKNOWN FIRST Trial Team
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Apr 4, 2015·Blood·Philippe MoreauThierry Facon
Jun 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ruben NiesvizkyJames Reeves
Aug 19, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboMario Boccadoro
Dec 13, 2017·The New England Journal of Medicine·María-Victoria MateosUNKNOWN ALCYONE Trial Investigators
Jan 18, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David S SiegelA Keith Stewart

❮ Previous
Next ❯

Citations

Jul 10, 2019·Leukemia & Lymphoma·Qaiser BashirMuzaffar H Qazilbash
Feb 27, 2020·Expert Opinion on Drug Safety·Omar Nadeem, Kenneth C Anderson
Feb 23, 2020·American Journal of Hematology·Rajshekhar Chakraborty, Navneet S Majhail
Jul 29, 2020·Blood Research·Sung-Hoon JungJe-Jung Lee
Aug 1, 2020·Expert Opinion on Emerging Drugs·Rajshekhar Chakraborty, Suzanne Lentzsch
Aug 6, 2019·American Journal of Hematology·Kristen M SanfilippoBrian F Gage
Dec 27, 2019·American Journal of Physiology. Cell Physiology·Paula Saavedra-GarcíaHolger W Auner
Jun 24, 2020·Journal of Hematology & Oncology·Leire BurgosJesús F San-Miguel
Jan 5, 2021·American Journal of Hematology·Susan BalLuciano J Costa
Sep 23, 2020·Panminerva Medica·Vittorio MontefuscoClaudio Cerchione
Dec 4, 2020·The Lancet Oncology·Shaji K KumarS Vincent Rajkumar
Sep 22, 2020·Panminerva Medica·Massimo GentileClaudio Cerchione
Nov 8, 2020·Journal of Clinical Medicine·Hélène GardeneyStéphanie Guidez
Mar 19, 2021·Expert Review of Hematology·Michel DelforgeNicolas Kint
Mar 23, 2021·British Journal of Haematology·Jonathan SiveUNKNOWN British Society of Haematology
Mar 17, 2021·American Journal of Hematology·Sarah Goldman-Mazur, Shaji K Kumar
Apr 20, 2021·Drugs·Radowan A Elnair, Sarah A Holstein
May 21, 2021·Journal of Proteome Research·David C KoomenKenneth H Shain
Jun 3, 2021·Cancers·Fredrik Schjesvold, Albert Oriol
Jun 20, 2021·Advances in Therapy·Hadi E Berbari, Shaji K Kumar
Jun 25, 2021·Therapeutic Advances in Hematology·Andrew J Yee
Jun 27, 2021·Cancer Treatment and Research Communications·A VisramW I Gonsalves
Apr 30, 2021·Haematologica·Monika EngelhardtJohannes Waldschmidt
Oct 5, 2021·Expert Review of Hematology·Paola TacchettiMichele Cavo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.